OCCURRENCE OF MACROLIDE LINCOSAMIDE STREPTOGRAMIN RESISTANCES AMONG STAPHYLOCOCCAL CLINICAL ISOLATES AT A UNIVERSITY MEDICAL-CENTER - IS FALSE SUSCEPTIBILITY TO NEW MACROLIDES AND CLINDAMYCIN A CONTEMPORARY CLINICAL AND INVITRO TESTING PROBLEM

A total of 2189 staphylococcal strains at the University of Iowa Hospitals and Clinics (Iowa City, IA) were initially screened to determine the incidence of constitutive (29.8%) and potential inducible macrolide-lincosamide-streptogramin (MLS) resistance (11.3%). Staphylococcus haemolyticus and S. epidermidis (62.5% and 55.3%) showed the highest incidence of constitutive resistance. Staphylococcus hominis had the highest incidence of inducible resistance (40.6%), while S. aureus had the lowest rate for both resistance types. The overall ratio of constitutive-inducible MLS resistance was 4:1. Among strains initially speciated using the Vitek System GPI card, there was only a 69% species identification reproducibility, and 78% accuracy versus a reference identification method. A random sample of 105 Staphylococcus spp. isolates with discordant macrolide (erythromycin resistant) and lincosamide (clindamycin susceptible) susceptibility patterns were tested against 16 antimicrobial agents by using a reference broth microdilution method. All erythromycin-resistant Staphylococcus spp. were also resistant to other 14-member macrolides and azithromycin, while all organisms remained susceptible to clindamycin, rifampin, vancomycin, and the streptogramin compounds (RP59500 and virginiamycin). Resistance to teicoplanin was identified among some oxacillin-resistant S. haemolyticus strains. Of 105 isolates, 65 (62%) showed inducible MLS resistance, 28 (27%) were noninducible, and 12 (11%) were either fully susceptible or resistant to the MLS drugs (Vitek System interpretation errors). MLS disk induction tests revealed two inducible resistance phenotypes: ML and MLS. Staphylococcus aureus showed the highest inducible resistance rate at 95% with an MLS-predominant pattern. In contrast, endemic S. haemolyticus isolates did not demonstrate inducible resistance that is, efflux-mediated erythromycin resistance. Due to the high incidence MLS resistance induction among S. aureus strains, we recommend (a) to test erythromycin routinely only to represent all current macrolides and lincosamides, and (b) to perform induction tests (disk diffusion or E-test methods) for coagulase-negative staphylococci isolated from serious, invasive infections especially before considering MLS compounds as an alternative therapeutic choice.